Disparities in Monoclonal Antibody Treatment of Elderly Metastatic Colorectal Cancer Patients

摘要: Disparities in Monoclonal Antibody Treatment of Elderly Metastatic Colorectal Cancer Patients by Krista Marie Schroeder MHS, Quinnipiac University, 2006 BS, The Ohio State 2004 Dissertation Submitted Partial Fulfillment the Requirements for Degree Doctor Philosophy Public Health Walden University August 2015 Abstract Multiple research studies have demonstrated racial, socioeconomic status (SES), and neighborhood disparities first-line treatment colorectal cancer patients, including those with metastatic cancer. However, adjunct monoclonal antibody not been explored. purpose this study was to assess SES, elderly patients. rooted 3 theories: fundamental cause theory, diffusion innovations theory health medical technology. Data from SEER-Medicare database logistic regression were used relationship between variables interest therapy. In study, race (p = 0.070), SES 0.881), characteristics 0.309) did significantly predict who would receive results a potential improvement historically documented disparities. Specifically, historical may be relevant newer therapiesMultiple therapies prescribed patients severe disease. difference could related improved access care or change paradigm due severity Future aimed at understanding causes social (i.e., reduced disparities) are warranted. Understanding root observed reduce other populations. Dedication I dedicate dissertation project my Uncle Mel, Grandpa Al, all survivors. also husband Andrew our daughter Katie. hope serves as inspiration that she should reach stars follow her dreams. Nothing is unreachable. Acknowledgments like thank Dr. Panas (chair; content expert), Fufaa (committee member; methodology expert) Thorpe (URR) serving on committee making possible. This linked database. interpretation reporting these data sole responsibility authors. authors acknowledge efforts National Institute; Office Research, Development Information, CMS; Information Management Services (IMS), Inc.; Surveillance, Epidemiology, End Results (SEER) Program tumor registries creation employed multiple SEER California Registry. Registry requires following statement: collection incidence supported Department part statewide program mandated Safety Code Section 103885; Institute's Epidemiology under contract HHSN261201000140C awarded Prevention Institute California, HHSN261201000035C Southern HHSN261201000034C Centers Disease Control Prevention's Registries, agreement # U58DP003862-01 Health. ideas opinions expressed herein author(s) endorsement Health, Institute, their Contractors Subcontractors intended nor inferred.